The Pandemic Institute (Legally hosted by the University of Liverpool)
The Pandemic Institute is a collaborative organization based in Liverpool, established in 2021, dedicated to tackling emerging infections and pandemic threats through research, innovation, and partnerships. It builds on Liverpool’s extensive history in infectious diseases research and aims to improve global health security by predicting, preparing, preventing, responding, and recovering from pandemics.
Industries
Nr. of Employees
large (251-1000)
The Pandemic Institute (Legally hosted by the University of Liverpool)
Products
Graphene-based biosensor prototype for mpox detection
Research project developing a graphene-enabled biosensor prototype for rapid detection of mpox, intended for point-of-care or field use.
Prototype rapid diagnostic tests (lateral flow and sensor-based)
Projects to design and develop rapid point-of-care diagnostic tests for priority pathogens, including lateral-flow formats and low-cost sensor concepts.
Environmental air-sampling device assessment
Laboratory and field evaluation of air-sampling devices for aerosol detection to inform environmental surveillance strategies.
Pre-clinical pipeline for influenza therapeutics
A funded pre-clinical testing pipeline for influenza therapeutics, incorporating translational planning and controlled human infection model considerations.
Lateral-flow antigen test development outputs
Project outputs including lateral-flow antigen tests for high-consequence pathogens developed by partner investigators and supported through targeted funding and strategic posts.
Graphene-based biosensor prototype for mpox detection
Research project developing a graphene-enabled biosensor prototype for rapid detection of mpox, intended for point-of-care or field use.
Prototype rapid diagnostic tests (lateral flow and sensor-based)
Projects to design and develop rapid point-of-care diagnostic tests for priority pathogens, including lateral-flow formats and low-cost sensor concepts.
Environmental air-sampling device assessment
Laboratory and field evaluation of air-sampling devices for aerosol detection to inform environmental surveillance strategies.
Pre-clinical pipeline for influenza therapeutics
A funded pre-clinical testing pipeline for influenza therapeutics, incorporating translational planning and controlled human infection model considerations.
Lateral-flow antigen test development outputs
Project outputs including lateral-flow antigen tests for high-consequence pathogens developed by partner investigators and supported through targeted funding and strategic posts.
Services
Contracted pre-clinical testing providing immunogenicity and efficacy data for vaccine candidates, therapeutics and experimental therapies using clinically relevant in vitro and in vivo models.
Design and delivery support for controlled human infection studies and first-in-human vaccine trials, including linkage to clinical research facilities.
Facilitated access to biosafety containment laboratories, clinical research facilities and regional manufacturing partners to support translational research and scale-up planning.
Analytical and surveillance support including next-generation surveillance design, epidemic simulation and data-driven evaluation of community testing interventions.
Coordination of national and regional academic networks to prioritise pandemic research, convene experts and connect academia, government and industry stakeholders.
Administration of short-term, targeted funding calls to mobilise resources for urgent pandemic preparedness projects, including prototype diagnostics, vaccines and data science.
Contracted pre-clinical testing providing immunogenicity and efficacy data for vaccine candidates, therapeutics and experimental therapies using clinically relevant in vitro and in vivo models.
Design and delivery support for controlled human infection studies and first-in-human vaccine trials, including linkage to clinical research facilities.
Facilitated access to biosafety containment laboratories, clinical research facilities and regional manufacturing partners to support translational research and scale-up planning.
Analytical and surveillance support including next-generation surveillance design, epidemic simulation and data-driven evaluation of community testing interventions.
Coordination of national and regional academic networks to prioritise pandemic research, convene experts and connect academia, government and industry stakeholders.
Administration of short-term, targeted funding calls to mobilise resources for urgent pandemic preparedness projects, including prototype diagnostics, vaccines and data science.
Expertise Areas
- Pandemic preparedness and response
- Diagnostics development and validation
- Pre-clinical vaccine and therapeutic testing
- Controlled human infection studies and clinical research
Key Technologies
- Controlled human infection models
- In vitro and in vivo infection models
- Human organoids and microphysiological systems
- Lateral-flow immunoassays and rapid antigen tests
News & Updates
A conference to showcase collaborative funded work and bring together industry, funders, and government collaborators.
Researchers from Liverpool involved in pioneering diagnostics work were recognized at Buckingham Palace.
UK government’s Chief Scientific Adviser visited Liverpool to learn about the work of The Pandemic Institute.
Liverpool led the world’s first voluntary mass testing for COVID-19, with evaluation showing significant impact.
Almost £700k awarded across four projects to enhance pandemic preparedness.
A £5m collaboration to develop influenza vaccines and improve pandemic response.
A conference to showcase collaborative funded work and bring together industry, funders, and government collaborators.
Researchers from Liverpool involved in pioneering diagnostics work were recognized at Buckingham Palace.
UK government’s Chief Scientific Adviser visited Liverpool to learn about the work of The Pandemic Institute.
Liverpool led the world’s first voluntary mass testing for COVID-19, with evaluation showing significant impact.
Almost £700k awarded across four projects to enhance pandemic preparedness.
A £5m collaboration to develop influenza vaccines and improve pandemic response.